Introduction 47 The reemergence of the Zika virus (ZIKV) in recent years as an infectious agent 48 of global concern has driven extensive scientific investigation into the pathology and 49 treatment of infection (1, 2) . This pathogen from the viral family Flaviviridae is 50 transmitted by Aedes sp. mosquitos and is associated with microcephaly in newborns 51 and neural-inflammatory diseases such as Guillain-Barré syndrome and 52 ophthalmological complications in adults (3, 4) . No approved therapy is currently 53 available to treat this infection, stressing the importance of developing new vaccines 54 and antivirals. 55 Viral polymerases remain attractive targets in the development of antivirals due 56 to their proven clinical usefulness and their essential activity in viral life cycles (5-7). 57 Nucleoside analogues abrogate nucleic acid synthesis and consequently viral genome recently identified numerous candidate inhibitors of ZIKV replication (8, 9) , including the 61 nucleoside analogue ProTide (prodrug nucleotide) sofosbuvir, a direct-acting antiviral 62 against the Hepatitis C virus (HCV) (10, 11) . Other nucleoside analogues that have 63 been investigated for anti-ZIKV activity (targeting the viral polymerase or nucleoside 64 biosynthesis) include 7-deaza-2´-C-methyladenosine (7-deaza-2'-CMA) (12, 13) , the 65 adenosine analogue NITD008 (14), 2'-C-methylribonucleosides (13, 15, 16) , 3'-O-66 methylribonucleosides (13), ribavirin (17) and 5-fluorouracil (18) . 67 Testing antiviral activity in cell-based phenotypic assays has been conducted in 68 many of these studies. Readouts of antiviral activity used to assess compound efficacy 69 3 and toxicity include qRT-PCR of viral RNA (19) , plaque reduction assays (13), cell-70 viability assays (18) of the wells were acquired using an ImageXpress Micro high-content imager with 10x 93 objective lens (Molecular Devices) ( Fig. 1a ). Cells were subsequently fixed with 4% 94 formaldehyde and stained with 4',6-diamidino-2-phenylindole (DAPI). The plates were 95 re-imaged to acquire pictures of the cell nuclei ( Fig. 1b ). Images were then analyzed 96 using a custom module in MetaXpress (Molecular Devices) to generate segmentation 97 counts of detached cells in bright-field, as well as segmentation counts of total cell 98 nuclei ( Fig. 1c and d ). Percent levels of CPE were determined by dividing the number of 99 detached cells by the total number of cell nuclei and multiplying by 100. Percent CPE 100 was normalized to the uninfected controls by subtracting the percent CPE in uninfected 101 controls from infected wells. Using 128 positive and 128 negative control wells, a Z' 102 value of 0.50 was obtained, which is comparable to those reported for other phenotypic 103 assays used to screen for ZIKV inhibitors (8, 9, 18) , and indicates that the assay is 104 useful as a primary screening tool for large compound libraries. Our method requires 105 only one short staining step (DAPI) and two sets of images to be taken to assess 106 antiviral activity, reducing the amount of sample manipulation and allowing for same-day 107 data acquisition.
109
Training of antiviral assay using published nucleoside analogues 110 We assessed the antiviral activity of a small training library of nucleoside 111 analogues and nucleoside analogue ProTides (25) (Fig. 2 ). Our selection of nucleoside 112 analogues for testing encompasses three types of structural features known to inhibit 113 viral polymerases by alternative mechanisms. The first category is obligate chain 114 terminators, which lack the 3′ hydroxyl group needed for elongation after incorporation 115 5 into a nascent RNA strand (13, 15) . We selected compounds that lack the 3′ hydroxyl 116 (i.e. replacing it with hydrogen) or that substitute a methoxy or fluoro group in its place 117 (Table 1 and Fig. 2 ). While having the potential for high potency against enzymatic RNA 118 synthesis when delivered as a nucleoside triphosphate, the 3′ modifications can 119 attenuate nucleoside phosphorylation in cells (26). The second category is non-obligate 120 chain terminators, which typically include 2′ modifications that block chain elongation for 121 conformational or steric reasons (11, 27) . In this category, we included the 2′-C-methyl 122 compounds previously shown to be active against ZIKV in cell-based assays, plus 123 additional modifications. Last, we included nucleobase modifications associated with 124 antiviral activity by lethal mutagenesis (28, 29) . While typically potent, these inhibition 125 mechanisms are often associated with greater cytotoxicity. Since some of the structural 126 modifications in these substrate analogues are known to be associated with reduced 127 nucleo(s/t)ide kinase compatibility, we prepared ProTide prodrugs for a selection of the 128 compounds (25). The ProTide nucleoside monophosphate masking strategy is used in 129 the clinically approved anti-HCV drug sofosbuvir (11). 130 Compounds were pre-spotted onto plates using an Acoustic Transfer System 131 instrument (EDC Biosciences) in a ten point, two-fold dose response from 100 µM to 132 0.197 µM. Vero cells and ZIKV were then added to the plate as described above and 133 incubated with compound for 72 hours. Bright-field and DAPI channel images were 134 acquired as described above; normalized percent activity was plotted versus In contrast with previously published reports that ribavirin has no effect on 156 preventing CPE in Vero cells (8), we observed a reduction in the number of detached 157 cells during ZIKV infection, as well as a reduction in ZIKV antigen production via 158 immunofluorescence when cells were treated with ribavirin at high concentrations (Fig. 159 5). This is most likely due to our direct visualization of CPE through cell imaging 160 7 techniques and the higher test concentration of ribavirin (up to 100 µM) used in this 161 study. 162 Interestingly, we found that sofosbuvir, which has been reported to inhibit ZIKV 163 (10, 11, 30) Screening of a novel library of natural products-derivatives using the developed assay 173 Although the design and synthesis will be reported elsewhere, here we briefly 174 describe our fragment-based approach towards the natural product-based small-175 molecule library used to validate our screening assay. We recently designed, 176 synthesized and reported marinopyrrole derivatives as potent anti-methicillin resistant 177 Staphylococcus aureus (MRSA) and anticancer agents (31-38). As shown in Figure 6 , 178 marinopyrroles 1a and 1b have clogP values of 6.5 and 6.1, respectively, which violates 179 Lipinski's rule of five (39). In order to improve physicochemical properties, we designed 180 a library containing 24 members with lower clogP values ranging from 2.1 to 5.0. We 181 performed structural simplification and optimization of these marinopyrrole derivatives 182 and came up with a novel series of pyrrolomycin-like derivatives (40, 41) . Compound 1 183 8 ( Fig. 6) , as one of the library members with a clogP value of 4.9, was fully characterized 184 using NMR and high resolution mass spectrometry. 185 Validation of the assay as a platform for the identification of new chemical entities 186 with anti-ZIKV activity was conducted using the library of 24 natural products (Fig. 6) . 187 Screening of the library revealed compound 1 as being able to prevent virus-induced 188 CPE, with an EC 50 of 5.95 µM and CC 50 of > 10 µM (Table 2) ; all 23 other compounds in 189 the library were inactive in our primary screening assay up to concentrations of 10 µM. 190 Reduction in viral antigen production upon treatment with compound 1 was also 191 observed in the immunofluorescence assay ( Fig. 7 ). Lastly, we tested compound 1 in a ZIKV infection in bright-field: a simple threshold from 0 to 65535 intensity units was 278 created. Next, a Gaussian filter with a sigma value of 2 was first applied to the image. 279 Using the multiply function, the product of these two images was generated and then 280 multiplied by 5000. A gradient was then applied to this result using a pixel size of 2. An 
